Product Name
MSF, Blocking Peptide
Product Synonym Names
Cell division control protein septin D1; MLL septin-like fusion protein MSF-A; MSF1; NAPB; Ov/Br septin; Ovarian/breast septin alpha; PNUTL4; SeptD1; Septin 9; Septin D1 antibody, ; SINT1 antibody
Product Gene Name
MSF blocking peptide
[Similar Products]
Antibody/Peptide Pairs
MSF peptide (MBS544443) is used for blocking the activity of MSF antibody (MBS544819)
Antibody/Peptide Pairs
MSF peptide (MBS544443) is used for blocking the activity of MSF antibody (MBS544820)
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q9UHD8
Form/Format
Antigenic Blocking Peptide
Concentration
Quantity: 250 ug; Volume: 100 ul (lot specific)
Immunogen
Synthetic Peptide
Expression
Widely expressed. Isoforms are differentially expressed in testes, kidney, liver heart, spleen, brain, peripheral blood leukocytes, skeletal muscle and kidney. Specific isoforms appear to demonstrate tissue specificity. Isoform 5 is the most highly expres
Molecular Function
GTPase activity
Subcellular Location
Cytoplasm, Cytoskeleton. (Note: in an epithelial cell line, concentrates at cell-cell contact areas. After TGF-beta1 treatment and induction of epithelial to mesenchymal transition, colocalizes partly with actin stress fivers. During bacterial infection,
Preparation and Storage
-20 degree C for long term storage
Other Notes
Small volumes of MSF blocking peptide vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
MSF blocking peptide
Antigenic Blocking Peptide Septin 9 Antibody
Filament-forming cytoskeletal GTPase (By similarity). May play a role in cytokinesis (Potential). May play a role in the internalization of 2 intracellular microbial pathogens, Listeria monocytogenes and Shigella flexneri.
Applications Tested/Suitable for MSF blocking peptide
Immunodepletion, Immunocompetition
Application Notes for MSF blocking peptide
Western Blot: 1:500
NCBI/Uniprot data below describe general gene information for MSF. It may not necessarily be applicable to this product.
NCBI Accession #
AAH21192.1
[Other Products]
UniProt Primary Accession #
Q9UHD8
[Other Products]
UniProt Secondary Accession #
Q96QF3; Q96QF4; Q96QF5; Q9HA04; Q9UG40; A8K2V3; B3KPM0; B4DTL9; B4E0N2; B4E274; B7Z654[Other Products]
UniProt Related Accession #
Q9UHD8[Other Products]
Molecular Weight
41,187 Da
NCBI Official Full Name
Septin 9
NCBI Official Synonym Full Names
septin 9
NCBI Official Symbol
SEPT9 [Similar Products]
NCBI Official Synonym Symbols
MSF; MSF1; NAPB; SINT1; PNUTL4; SeptD1; AF17q25
[Similar Products]
NCBI Protein Information
septin-9
UniProt Protein Name
Septin-9
UniProt Synonym Protein Names
MLL septin-like fusion protein MSF-A; MLL septin-like fusion protein; Ovarian/Breast septin; Ov/Br septin; Septin D1
UniProt Gene Name
SEPT9 [Similar Products]
UniProt Synonym Gene Names
KIAA0991; MSF; MLL septin-like fusion protein; Ov/Br septin [Similar Products]
UniProt Entry Name
SEPT9_HUMAN
NCBI Summary for MSF
This gene is a member of the septin family involved in cytokinesis and cell cycle control. This gene is a candidate for the ovarian tumor suppressor gene. Mutations in this gene cause hereditary neuralgic amyotrophy, also known as neuritis with brachial predilection. A chromosomal translocation involving this gene on chromosome 17 and the MLL gene on chromosome 11 results in acute myelomonocytic leukemia. Multiple alternatively spliced transcript variants encoding different isoforms have been described.[provided by RefSeq, Mar 2009]
UniProt Comments for MSF
Filament-forming cytoskeletal GTPase (). May play a role in cytokinesis (Potential). May play a role in the internalization of 2 intracellular microbial pathogens, Listeria monocytogenes and Shigella flexneri.
Research Articles on MSF
1. KRAS mutations and SEPT9 promoter methylation were present in 34% (29/85) and in 82% (70/85) of primary tumor tissue samples.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
